Table 1.
Patient Demographics
| Demographic | Azithromycin (n=152) | Control (n=585) | p-value |
|---|---|---|---|
| Prior to admission | |||
| Age (years) | 61 (50–70) | 56 (45–66) | 0.001 |
| Sex (% male) | 98 (64.5%) | 313 (53.5%) | 0.015 |
| Race (% white) | 132 (86.8%) | 519 (88.7%) | 0.685 |
| Height (cm) | 173 (165–180) | 173 (163–178) | 0.185 |
| Weight (kg) | 83 (70–100) | 81 (68–100) | 0.239 |
| Baseline serum creatinine (mg/dl) | 1.0 (0.8–1.1) | 0.9 (0.7–1.0) | 0.011 |
| Baseline eGFR (ml/min/1.73 m2) | 77 (64–97) | 87 (67–105) | 0.016 |
| Diabetes (%) | 48 (31.6%) | 202 (34.5%) | 0.494 |
| Hypertension (%) | 99 (65.1%) | 376 (64.3%) | 0.844 |
| Coronary artery disease (%) | 54 (35.5%) | 183 (31.3%) | 0.318 |
| Heart failure (%) | 48 (31.6%) | 132 (22.6%) | 0.021 |
| Liver disease (%) | 40 (26.3%) | 182 (31.1%) | 0.251 |
| Chronic kidney disease (%) | 39 (25.7%) | 127 (21.7%) | 0.299 |
| Hospital admission | |||
| KDIGO AKI stage | <0.001 | ||
| 1 | 84 (55.3%) | 223 (38.1%) | |
| 2 | 37 (24.3%) | 156 (26.7%) | |
| 3 | 31 (20.4%) | 206 (35.2%) | |
| Serum lactate (mmol/l) | 0.9 (0.4–1.9) | 1.0 (0.5–3.3) | 0.03 |
| SOFA score | 9 (6–13) | 9 (6–13) | 0.393 |
| Anti-pseudomonal antibiotic coverage (%) | 103 (67.8%) | 444 (75.9%) | 0.041 |
| Vasopressor requirement within 48 hours of admission (%) | 109 (71.7%) | 438 (74.9%) | 0.427 |
| Duration of azithromycin treatment (days) | 3 (2–5) | 0 (0–0) | <0.001 |
eGFR=estimated glomerular filtration rate; KDIGO=Kidney Disease Improving Global Outcomes; SOFA=Sequential Organ Failure Assessment